TCGA-CQ-6228-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.104109589
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
- OXIDATIVE_PHOSPHORYLATION+0.360
- HYPOXIA+0.340
- MYC_TARGETS_V1+0.320
- PANCREAS_BETA_CELLS+0.260
- MTORC1_SIGNALING+0.250
- FATTY_ACID_METABOLISM+0.220
- GLYCOLYSIS+0.220
- HEDGEHOG_SIGNALING+0.220
- UV_RESPONSE_UP+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.440
- APICAL_SURFACE-0.420
- IL6_JAK_STAT3_SIGNALING-0.420
- INTERFERON_GAMMA_RESPONSE-0.420
- INFLAMMATORY_RESPONSE-0.330
- COMPLEMENT-0.300
- COAGULATION-0.280
- APICAL_JUNCTION-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.782 |
| 2 | MNG999 | — | — | 0.781 |
| 3 | TCGA-UF-A71E-01A-31R-A34R-07 | — | — | 0.776 |
| 4 | ULC1533T_S61 | — | cohortA2 | 0.770 |
| 5 | ccfdc2a2-bb01-41c2-9ef1-98bbd1cfae22 | — | — | 0.762 |
| 6 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.755 |
| 7 | 56D3154E-E779-4C27-8305-FEE7310B6762 | — | — | 0.754 |
| 8 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.752 |
| 9 | MDT-AP-0580 | Med | Medulloblastoma | 0.747 |
| 10 | MDT-AP-2020 | Med | Medulloblastoma | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |